Oncolytics Biotech® Strengthens Leadership Team With John McAdory As EVP And Yujun Wu As Head Of Biostatistics

Oncolytics Biotech Inc., a clinical-stage immunotherapy company developing pelareorep, announced the appointments of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These additions are expected to strengthen the company’s operational, clinical, and regulatory capabilities as Oncolytics advances its registration-directed development programs in pancreatic, colorectal, and anal cancers.

In his new role, John McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the company’s portfolio. He brings extensive experience in leading late-stage oncology programs, particularly within the oncolytic virus field. Most recently, Mr. McAdory served as Vice President of Clinical Operations at CG Oncology, Inc., a late-stage biotechnology company developing an intratumoral oncolytic virus. Throughout his career, he has managed large, registration-directed clinical trials involving hundreds of patients across multiple tumor types and has supported global regulatory interactions.

Jared Kelly, Chief Executive Officer of Oncolytics, said, “John’s background in managing complex, late-stage oncology trials makes him exceptionally well-suited to lead Oncolytics’ next phase of execution. As we advance pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical in ensuring disciplined execution, efficiency, and regulatory alignment.”

Yujun Wu joins Oncolytics as Vice President, Head of Biostatistics, bringing deep expertise in statistical strategy, regulatory interactions, and late-stage trial design. Previously, Mr. Wu served as Head of Biostatistics at Morphic Therapeutic, supporting multiple clinical programs through late-stage development and playing a key role in the company’s acquisition by Eli Lilly and Company. He also led statistical strategy and regulatory execution for multiple Phase 3 and registration oncology programs at Takeda Pharmaceutical Company Limited, applying innovative trial designs to accelerate late-stage development and secure global regulatory approvals.

Mr. Kelly added, “Yujun’s experience in designing and supporting late-stage studies and engaging with regulators significantly strengthens our internal capabilities. As we pursue accelerated approval strategies and pivotal trials, high-quality statistical leadership is essential, and Yujun brings that expertise at a crucial time for the company.”

These appointments align with Oncolytics’ strategic focus on advancing pelareorep through the most efficient regulatory pathways. The company continues to prioritize indications with high unmet medical needs, clear clinical signals, and defined accelerated approval opportunities, including squamous cell anal cancer, pancreatic cancer, and KRAS-mutant colorectal cancer.